As an FDA decision draws closer on bluebird bio’s sickle cell disease gene therapy, the company has lined up a potential sale of a priority review voucher (PRV). The agreement, worth $103 million, ...
Day-45 MRD clearance favored cema-cel over observation by an absolute 41.6% in the first 24 evaluable patients, satisfying ...
Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...
Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. New research offers insights into the use of axicabtagene ciloleucel (axi-cel), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results